Association between integrin-linked kinase and hyperthermia in oral squamous cell carcinoma

Jun Zhao1,2, Na Liu2,3, Xinhe Hao1

  • 1Department of Oral and Maxillofacial Surgery, Hefei Stomatological Hospital, Hefei, Anhui 230001, P.R. China.

Oncology Letters
|December 19, 2017
PubMed

Insights

Combining integrin-linked kinase (ILK) silencing with hyperthermia effectively inhibits oral squamous cell carcinoma (OSCC) growth and promotes apoptosis. This novel combination therapy shows significant therapeutic effects in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Oral squamous cell carcinoma (OSCC) is a significant global health concern.
  • Integrin-linked kinase (ILK) plays a crucial role in cancer cell proliferation and migration.
  • Targeting ILK offers a potential therapeutic strategy for OSCC.

Purpose of the Study:

  • To investigate the combined effects of ILK silencing and hyperthermia on OSCC Tca8113 cells.
  • To evaluate the therapeutic efficacy of this combination in preclinical OSCC models.
  • To elucidate the underlying molecular mechanisms of the combined treatment.

Main Methods:

  • Lentivirus-mediated short hairpin RNA (shRNA) for ILK gene silencing.
  • In vitro cell culture assays to assess cell growth, migration, and apoptosis.
  • In vivo studies using nude mice xenograft models.
  • Western blot and immunohistochemistry to analyze protein expression.

Main Results:

  • ILK silencing combined with hyperthermia significantly inhibited Tca8113 cell growth, proliferation, and migration.
  • The combination therapy induced cell cycle arrest at the S phase and promoted apoptosis.
  • Key proteins in the PI3K/Akt pathway and heat shock factor 1 were downregulated, while apoptosis markers were upregulated.
  • Significant tumor regression was observed in vivo, with results consistent with in vitro findings.

Conclusions:

  • ILK silencing combined with hyperthermia demonstrates a synergistic therapeutic effect against OSCC.
  • This combination strategy effectively inhibits tumor growth, enhances apoptosis, and modulates key signaling pathways.
  • ILK silencing and hyperthermia represent a promising novel combination therapy for OSCC treatment.

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
3.7K
Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
5.2K
Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.7K